Advertisement

Sensory Nerves pp 393-416 | Cite as

Sensory-Nerve-Derived Neuropeptides: Possible Therapeutic Targets

  • Elizabeth S. Fernandes
  • Sabine M. Schmidhuber
  • Susan D. BrainEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 194)

Abstract

This review examines our developing understanding of the families and activities of some of the best known sensory-nerve-derived inflammatory neuropeptides, namely substance P, calcitonin gene-related peptide and galanin. Evidence to date shows involvement of these transmitters in a wide range of systems that includes roles as inflammatory modulators. There is an increasing understanding of the mechanisms involved in the release of the peptides from sensory nerves and these are key in understanding the potential of neuropeptides in modulating inflammatory responses and may also provide novel targets for anti-inflammatory therapy. The neuropeptides released act via specific G protein coupled receptors, most of which have now been cloned. There is knowledge of selective agonists and antagonists for many subtypes within these families. The study of neuropeptides in animal models has additionally revealed pathophysiological roles that in turn have led to the development of new drugs, based on selective receptor antagonism.

Keywords

Neuropeptides Substance P CGRP Galanin 

Abbreviations

AM

Adrenomedullin

AM1

Adrenomedullin receptor type 1

AM2

Adrenomedullin receptor type 2

CGRP

Calcitonin gene-related peptide

CL

Calcitonin receptor-like receptor

DRG

Dorsal root ganglia

GAL

Galanin

GALP

Galanin-like peptide

GMAP

Galanin-message-associated peptide

mRNA

Messenger RNA

NKA

Neurokinin A

NKB

Neurokinin B

RAMP

Receptor activity modifying protein

SP

Substance P

TRPV1

Transient receptor potential vanilloid 1

Notes

Acknowledgement

E.S.F. is funded by the Arthritis Research Campaign and by a postdoctoral grant from Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil).

References

  1. Ahmed M, Bjurholm A, Srinivasan GR, Lundeberg T, Theodorsson E, Schultzberg M, Kreicbergs A (1995) Capsaicin effects on substance P and CGRP in rat adjuvant arthritis. Regul Pept 55:85–102PubMedGoogle Scholar
  2. Ahren B, Wierup N, Sundler F (2006) Neuropeptides and the regulation of islet function. Diabetes 55(Suppl 2):S98–S107Google Scholar
  3. Ahrens B, Lindskog S (1992) Galanin and the regulation of islet hormone secretion. Int J Pancreatol 1:147–160Google Scholar
  4. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ (1995) Neuropeptides and general neuronal marker in psoriasis – an immunohistochemical study. Clin Exp Dermatol 20:384–389PubMedGoogle Scholar
  5. Ansel JC, Brown JR, Payan DG, Brown MA (1993) Substance P selectively activates TNF-α gene expression in murine mast cells. J Immunol 150:4478–4485PubMedGoogle Scholar
  6. Bartfai T, Hokfelt T, Langel U (1993) Galanin – a neuroendocrine peptide. Crit Rev Neurobiol 7:229–274PubMedGoogle Scholar
  7. Bauer FE, Zintel A, Kenny MJ, Calder D, Ghatei MA, Bloom SR (1989) Inhibitory effect of galanin on postprandial gastrointestinal motility and gut hormone release in humans. Gastroenterology 97:260–264PubMedGoogle Scholar
  8. Bayliss WM (1901) On the origin from the spinal cord of the vaso-dilator fibres of the hind-limb, and on the nature of these fibres. J Physiol 26:173–209PubMedGoogle Scholar
  9. Beer S, Weighardt H, Emmanuilidis K, Harzenetter MD, Matevossian E, Heidecke CD, Bartels H, Siewert JR, Holzmann B (2002) Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis. Crit Care Med 30:1794–1798PubMedGoogle Scholar
  10. Bevan S, Hothi S, Hughes G, James IF, Rang HP, Shah K, Walpole CS, Yeats JC (1992) Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol 107:544–552PubMedGoogle Scholar
  11. Bienenstock J, Tomioka M, Matsuda H, Stead RH, Quinonez G, Simon GT, Coughlin MD, Denburg JA (1987) The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int Arch Allergy Appl Immunol 82:238–243PubMedGoogle Scholar
  12. Blum AM, Metwali A, Cook G, Mathew RC, Elliott D, Weinstock JV (1993) Substance P modulates antigen-induced, IFN-gamma production in murine Schistosomiasis mansoni. J Immunol 151:225–233PubMedGoogle Scholar
  13. Blum AM, Metwali A, Kim-Miller M, Li J, Qadir K, Elliott DE, Lu B, Fabry Z, Gerard N, Weinstock JV (1999) The substance P receptor is necessary for a normal granulomatous response in murine schistosomiasis mansoni. J Immunol 162:6080–6085PubMedGoogle Scholar
  14. Botella A, Delvaux M, Bueno L, Frexinos J (1992) Intracellular pathways triggered by galanin to induce contraction of pig ileum smooth muscle cells. J Physiol 458:475–486PubMedGoogle Scholar
  15. Brain SD, Cox HM (2006) Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 147(Suppl 1):S202–S211PubMedGoogle Scholar
  16. Brain SD, Grant AD (2004) Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84:903–934PubMedGoogle Scholar
  17. Brain SD, Williams TJ (1985) Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 86:855–860PubMedGoogle Scholar
  18. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54–56PubMedGoogle Scholar
  19. Brodish RJ, Kuvshinoff BW, Fink AS, McFadden DW (1994) Inhibition of pancreatic exocrine secretion by galanin. Pancreas 9:297–303PubMedGoogle Scholar
  20. Brown DR, Hildebrand KR, Parsons AM, Soldani G (1990) Effects of galanin on smooth muscle and mucosa of porcine jejunum. Peptides 11:497–500PubMedGoogle Scholar
  21. Buck SH (1988) Multiple receptors for the tachykinin peptides. Proc West Pharmacol Soc 31: 45–47PubMedGoogle Scholar
  22. Bulling DG, Kelly D, Bond S, McQueen DS, Seckl JR (2001) Adjuvant-induced joint inflammation causes very rapid transcription of beta-preprotachykinin and alpha-CGRP genes in innervating sensory ganglia. J Neurochem 77:372–382PubMedGoogle Scholar
  23. Burgevin MC, Loquet I, Quarteronet D, Habert-Ortoli E (1995) Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. J Mol Neurosci 6:33–41PubMedGoogle Scholar
  24. Campos MM, Calixto JB (2000) Neurokinin mediation of edema and inflammation. Neuropeptides 34:314–322PubMedGoogle Scholar
  25. Castagliuolo I, LaMont JT, Letourneau R, Kelly C, O'Keane JC, Jaffer A, Theoharides TC, Pothoulakis C (1994) Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 107:657–665PubMedGoogle Scholar
  26. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816–824PubMedGoogle Scholar
  27. Chahl LA (2004) Hydrogen sulphide: an endogenous stimulant of capsaicin-sensitive primary afferent neurons? Br J Pharmacol 142:1–2PubMedGoogle Scholar
  28. Chan J, Smoller BR, Raychauduri SP, Jiang WY, Farber EM (1997) Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 289:611–616PubMedGoogle Scholar
  29. Chan-Palay V (1988) Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol 273:543–557PubMedGoogle Scholar
  30. Chawla SP, Grunberg SM, Gralla RJ et al (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97: 2290–2300PubMedGoogle Scholar
  31. Clark N, Keeble J, Fernandes ES, Starr A, Liang L, Sugden D, de Winter P, Brain SD (2007) The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin. FASEB J 21:3747–3755PubMedGoogle Scholar
  32. Courtice GP, Hales JR, Potter EK (1994) Selective regional vasoconstriction underlying pressor effects of galanin in anaesthetized possums compared with cats. J Physiol 481:439–45PubMedGoogle Scholar
  33. Crawley JN (1999) The role of galanin in feeding behavior. Neuropeptides 33:369–375PubMedGoogle Scholar
  34. Cunningham MJ (2004) Galanin-like peptide as a link between metabolism and reproduction. J Neuroendocrinol 16:717–723PubMedGoogle Scholar
  35. Dagar S, Onyüksel H, Akhter S, Krishnadas A, Rubinstein I (2003) Human galanin expresses amphipathic properties that modulate its vasoreactivity in vivo. Peptides 24:1373–1380PubMedGoogle Scholar
  36. Delvaux M, Botella A, Fioramonti J, Frexinos J, Bueno L (1991) Galanin induces contraction of isolated cells from circular muscle layer of pig ileum. Regul Pept 32:369–374PubMedGoogle Scholar
  37. Diz DI, Jessup JA, Westwood BM, Bosch SM, Vinsant S, Gallagher PE, Averill DB (2002) Angiotensin peptides as neurotransmitters/neuromodulators in the dorsomedial medulla. Clin Exp Pharmacol Physiol 29:473–482PubMedGoogle Scholar
  38. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420–423PubMedGoogle Scholar
  39. Doods H, Arndt K, Rudolf K (2007) CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 28:580–587PubMedGoogle Scholar
  40. Dzurik MV, Diedrich A, Black B, Paranjape SY, Raj SR, Byrne DW, Robertson D (2007) Endogenous substance P modulates human cardiovascular regulation at rest and during orthostatic load. J Appl Physiol 102:2092–2097PubMedGoogle Scholar
  41. Elliott-Hunt CR, Marsh B, Bacon A, Pope R, Vanderplank P, Wynick D (2004) Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci USA 101:5105–5110PubMedGoogle Scholar
  42. Evans HF, Shine J (1991) Human galanin: Molecular cloning reveals a unique structur. Endocrinology 129:1682–1684PubMedGoogle Scholar
  43. Eysselein VE, Nast CC (1991) Neuropeptides and inflammatory bowel disease. Z Gastroenterol Verh 26:253–257PubMedGoogle Scholar
  44. Fathi Z, Battaglino PM, Iben LG et al (1998) Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mol Brain Res 58:156–169PubMedGoogle Scholar
  45. Feistritzer C, Clausen J, Sturn DH, Djanani A, Gunsilius E, Wiedermann CJ, Kähler CM (2003) Natural killer cell functions mediated by the neuropeptide substance P. Regul Pept 116:119–126PubMedGoogle Scholar
  46. Ferrell WR, Lockhart JC, Karimian SM (1997) Tachykinin regulation of basal synovial blood flow. Br J Pharmacol 121:29–34PubMedGoogle Scholar
  47. Flatters SJ, Fox AJ, Dickenson A (2002) Nerve injury induces plasticity that results in spinal inhibitory effects of galanin. Pain 98:249–258PubMedGoogle Scholar
  48. Flowe KM, Lally KM, Mulholland MW (1992) Galanin inhibits rat pancreatic amylase release via cholinergic suppression. Peptides 13:487–492PubMedGoogle Scholar
  49. Foreman JC, Jordan CC, Piotrowski W (1983) Interaction of neurotensin with the substance P receptor mediating histamine release from rat mast cells and the flare in human skin. 77:531–539Google Scholar
  50. Foster AP, Cunningham FM (2003) Substance P induces activation, adherence and migration of equine eosinophils. J Vet Pharmacol Ther 26:131–138PubMedGoogle Scholar
  51. Fraley GS, Thomas-Smith SE, Acohido BV, Steiner RA, Clifton DK (2004) Stimulation of sexual behavior in the male rat by galanin-like peptide. Horm Behav 46:551–557PubMedGoogle Scholar
  52. Garrett NE, Kidd BL, Cruwys SC, Tomlinson DR (1995) Changes in preprotachykinin mRNA expression and substance P levels in dorsal root ganglia of monoarthritic rats: comparison with changes in synovial substance P levels. Brain Res 675:203–207Google Scholar
  53. Germonpré PR, Joos GF, Pauwels RA (1995) Characterization of the neurogenic plasma extravasation in the airways. Arch Int Pharmacodyn Ther 329:185–203PubMedGoogle Scholar
  54. Goetzl EJ, Chernov T, Renold F, Payan DG (1985) Neuropeptide regulation of the expression of immediate hypersensitivity. J Immunol 135:802s–805sPubMedGoogle Scholar
  55. Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrota DJ, Iyengar S (2000) Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther 67:419–426PubMedGoogle Scholar
  56. Gottsch ML, Clifton DK, Steiner RA (2004) Galanin-like peptide as a link in the integration of metabolism and reproduction. Trends Endocrinol Metab 15:215–221PubMedGoogle Scholar
  57. Gradl G, Finke B, Schattner S, Gierer P, Mittlmeier T, Vollmar B (2007) Continuous intra-arterial application of substance P induces signs and symptoms of experimental complex regional pain syndrome (CRPS) such as edema, inflammation and mechanical pain but no thermal pain. Neuroscience 148:757–765PubMedGoogle Scholar
  58. Green PG, Basbaum AI, Levine JD (1992) Sensory neuropeptide interactions in the production of plasma extravasation in the rat. Neuroscience 50:745–749PubMedGoogle Scholar
  59. Gross KJ, Pothoulakis C (2007) Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 13:918–932PubMedGoogle Scholar
  60. Gundlach AL (2002) Galanin/GALP and galanin receptors: Role in central control of feeding, body weight/obesity and reproduction? Eur J Pharmaol 440:255–268Google Scholar
  61. Hao JX, Shi TJ, Xu IS, Kaupilla T, Xu XJ, Hökfelt T, Bartfai T, Wiesenfeld-Hallin Z (1999) Intrathecal galanin alleviates allodynia-like behaviour in rats after partial peripheral nerve injury. Eur J Neurosci 11:427–432PubMedGoogle Scholar
  62. Herzig KH, Brunke G, Schön I, Schäffer M, Fölsch UR (1993) Mechanism of galanin's inhibitory action on pancreatic enzyme secretion: Modulation of cholinergic transmission-studies in vivo and in vitro. Gut 34:1616–1621PubMedGoogle Scholar
  63. Hökfelt T, Wiesenfeld-Hallin Z, Villar M, Melander T (1987) Increase of galanin-like immunoreactivity in rat dorsal root ganglion cells after peripheral axotomy. Neurosci Lett 83:217–220PubMedGoogle Scholar
  64. Holmes FE, Mahoney S, King VR, Bacon A, Kerr NC, Pachnis V, Curtis R, Priestley JV, Wynick D (2000) Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. Proc Natl Acad Sci USA 97:1563–11568Google Scholar
  65. Holmes FE, Mahoney SA, Wynick D (2005) Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injury. Neuropeptides 39:191–199PubMedGoogle Scholar
  66. Holzer P (1998) Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 30:5–11PubMedGoogle Scholar
  67. Holzer-Petsche U (1995) Tachykinin receptors in gastrointestinal motility. Regul Pept 57:19–42PubMedGoogle Scholar
  68. Hong SK, Han JS, Min SS, Hwang JM, Kim YI, Na HS, Yoon YW, Han HC (2002) Local neurokinin-1 receptor in the knee joint contributes to the induction, but not maintenance, of arthritic pain in the rat. Neurosci Lett 322:21–24PubMedGoogle Scholar
  69. Ikeda Y, Takei H, Matsumoto C, Mase A, Yamamoto M, Takeda S, Ishige A, Watanabe K (2007) Administration of substance P during a primary immune response amplifies the secondary immune response via a long-lasting effect on CD8+ T lymphocytes. Arch Dermatol Res 299:345–351PubMedGoogle Scholar
  70. Iwasaki A, Inoue K, Hukuda S (1995) Distribution of neuropeptide-containing nerve fibers in the synovium and adjacent bone of the rat knee joint. Clin Exp Rheumatol 13:173–178PubMedGoogle Scholar
  71. Jancsó N, Jancsó-Gabor A, Szolcsanyi J (1967) Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother 31:138–151PubMedGoogle Scholar
  72. Jancsó G, Kiraly E, Jancsó-Gabor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. Nature 270:741–743PubMedGoogle Scholar
  73. Jancsó G, Sántha P, Horváth V, Pierau F (2000) Inhibitory neurogenic modulation of histamine-induced cutaneous plasma extravasation in the pigeon. Regul Pept 95:75–80PubMedGoogle Scholar
  74. Jeanjean AP, Moussaoui SM, Maloteaux JM, Laduron PM (1995) Interleukin-1β induces long-term increase of axonally transported opiate receptors and substance P. Neuroscience 68:151–157PubMedGoogle Scholar
  75. Ji RR, Zhang X, Zhang Q, Dagerlind A, Nilsson S, Wiesenfeld-Hallin Z, Hökfelt T (1995) Central and peripheral expression of galanin in response to inflammation. Neuroscience 68:563–576PubMedGoogle Scholar
  76. Jiang WY, Raychaudhuri SP, Farber EM (1998) Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol 37:572–574PubMedGoogle Scholar
  77. Joos GF, Kips JC, Peleman RA, Pauwels RA (1995) Tachykinin antagonists and the airways. Arch Int Pharmacodyn Ther 329:205–219PubMedGoogle Scholar
  78. Juréus A, Cunningham MJ, Li D, Johnson LL, Krasnow SM, Teklemichael DN, Clifton DK, Steiner RA (2001) Distribution and regulation of galanin-like peptide (GALP) in the hypothalamus of the mouse. Endocrinology 142:5140–5144PubMedGoogle Scholar
  79. Kähler CM, Sitte BA, Reinisch N, Wiedermann CJ (1993) Stimulation of the chemotactic migration of human fibroblasts by substance P. Eur J Pharmacol 249:281–286PubMedGoogle Scholar
  80. Kar S, Rees RG, Quirion R (1994) Altered calcitonin gene-related peptide, substance P and enkephalin immunoreactivities and receptor binding sites in the dorsal spinal cord of the polyarthritic rat. Eur J Neurosci 6:345–354PubMedGoogle Scholar
  81. Keeble JE, Brain SD (2004) A role for substance P in arthritis? Neurosci Lett 361:176–179PubMedGoogle Scholar
  82. Kerr BJ, Cafferty WB, Gupta YK, Bacon A, Wynick D, McMahon SB, Thompson SW (2000) Galanin knockout mice reveal nociceptive deficits following peripheral nerve injury. Eur J Neurosci 12:793–802PubMedGoogle Scholar
  83. Kerr BJ, Gupta Y, Pope R, Thompson SW, Wynick D, McMahon SB (2001) Endogenous galanin potentiates spinal nociceptive processing following inflammation. Pain 93:267–277PubMedGoogle Scholar
  84. Khan WI, Collins SM (2004) Immune-mediated alteration in gut physiology and its role in host defence in nematode infection. Parasite Immunol 26:319–326PubMedGoogle Scholar
  85. Khawaja AM, Rogers DF (1996) Tachykinins: receptor to effector. Int J Biochem Cell Biol 28:721–738PubMedGoogle Scholar
  86. Kincy-Cain T, Bost KL (1996) Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II. J Immunol 157:255–264PubMedGoogle Scholar
  87. Kinney JW, Starosta G, Holmes A, Wrenn CC, Yang RJ, Harris AP, Long KC, Crawley JN (2002) Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. Learn Mem 9:178–190Google Scholar
  88. Kisfalvi I Jr, Burghardt B, Bálint A, Zelles T, Vizi ES, Varga G (2000) Antisecretory effects of galanin and its putative antagonists M15, M35 and C7 in the rat stomach. J Physiol Paris 94:37–42PubMedGoogle Scholar
  89. Kolakowski LF, O'Neill GP, Howard AD et al (1998) Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem 71:2239–2251PubMedGoogle Scholar
  90. Konttinen YT, Hukkanen M, Segerberg M, Rees R, Kemppinen P, Sorsa T, Saari H, Polak JM, Santavirta S (1992) Relationship between neuropeptide immunoreactive nerves and inflammatory cells in adjuvant arthritic rats. Scand J Rheumatol 21:55–59PubMedGoogle Scholar
  91. Koon HW, Pothoulakis C (2006) Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann N Y Acad Sci 1088:23–40PubMedGoogle Scholar
  92. Kramer MS, Winokur A, Kelsey J et al (2004) Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29:385–392PubMedGoogle Scholar
  93. Krasnow SM, Fraley GS, Schuh SM, Baumgartner JW, Clifton DK, Steiner RA (2003) A role of galanin-like peptide in the integration of feeding, body weight regulation, and reproduction in the mouse. Endocrinology 144:813–822PubMedGoogle Scholar
  94. Lam FY, Wong MC (1996) Characterization of tachykinin receptors mediating plasma extravasation and vasodilatation in normal and acutely inflamed knee joints of the rat. Br J Pharmacol 118:2107–2114PubMedGoogle Scholar
  95. Lam FY, Ferrell WR, Scott DT (1993) Substance P-induced inflammation in the rat knee joint is mediated by neurokinin 1 (NK1) receptors. Regul Pept 46:198–201PubMedGoogle Scholar
  96. Landry M, Roche D, Vila-Porcile E, Calas A (2000) Effects of centrally administered galanin (1–16) on galanin expression in the rat hypothalamus. Peptides 21:1725–1733PubMedGoogle Scholar
  97. Landry M, Liu HX, Shi TJ, Brumovsky P, Nagy F, H­kfelt T (2005) Galaninergic mechanisms at the spinal level: focus on histochemical phenotyping. Neuropeptides 39:223–231Google Scholar
  98. Lang R, Gundlach AL, Kofler B (2007) The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 115:177–207PubMedGoogle Scholar
  99. Larm JA, Gundlach AL (2000) Galanin-like peptide (GALP) mRNA expression is restricted to arcuate nucleus of hypothalamus in adult male rat brain. Neuroendocrinology 72:67–71PubMedGoogle Scholar
  100. Lecci A, Capriati A, Maggi CA (2004) Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 141:1249–1263PubMedGoogle Scholar
  101. Lewis T, Zotterman Y (1927) Vascular reactions of the skin to injury: part VIII. The resistance of the human skin to constant currents, in relation to injury and vascular response. J Physiol 62:280–288PubMedGoogle Scholar
  102. Lindsey KQ, Caughman SW, Olerud JE, Bunnett NW, Armstrong CA, Ansel JC (2000) Neural regulation of endothelial cell-mediated inflammation. J Investig Dermatol Symp Proc 5:74–78PubMedGoogle Scholar
  103. Liu H, Hockfelt T (2002) The participation of galanin in pain processing at the spinal level. Trends Pharmacol Sci 23:468–474PubMedGoogle Scholar
  104. Liu HX, Brumovsky P, Schmidt R, Brown W, Payza K, Hodzic L, Pou C, Godbout C, Hökfelt T (2001) Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci USA 98:9960–9964PubMedGoogle Scholar
  105. Maggi CA (1995) The mammalian tachykinin receptors. Gen Pharmacol 26:911–944PubMedGoogle Scholar
  106. Maggi CA (1997) Tachykinins as peripheral modulators of primary afferent nerves and visceral sensitivity. Pharmacol Res 36:153–169PubMedGoogle Scholar
  107. Mahoney SA, Hosking R, Farrant S, Holmes FE, Jacoby AS, Shine J, Iismaa TP, Scott MK, Schmidt R, Wynick D (2003) The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J Neurosci 23:416–421PubMedGoogle Scholar
  108. Matsumoto Y, Watanabe T, Adachi Y, Itoh T, Ohtaki T, Onda H, Kurokawa T, Nishimura O, Fujino M (2002) Galanin-like peptide stimulates food intake in the rat. Neurosci Lett 322:67–69PubMedGoogle Scholar
  109. Mazarati A, Lu X, Kilk K, Langel U, Wasterlain C, Bartfai T (2004) Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 19:3235–3244Google Scholar
  110. McDonald AC, Schuijers JA, Shen PJ, Gundlach AL, Grills BL (2003) Expression of galanin and galanin receptor-1 in normal bone and during fracture repair in the rat. Bone 33:788–797PubMedGoogle Scholar
  111. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333–339PubMedGoogle Scholar
  112. Mufson EJ, Cochran E, Benzing W, Kordower JH (1993) Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging. Alzheimer's disease and Down's syndrome. Dementia 4:237–250PubMedGoogle Scholar
  113. Mulholland MW, Schoeneich S, Flowe K (1992) Galanin inhibition of enteric cholinergic neurotransmission: Guanosine triphosphate-binding protein interactions with adenylate cyclase. Surgery 112:195–201Google Scholar
  114. Mungan Z, Ozmen V, Ertan A, Coy DH, Baylor LM, Rice JC, Rossowski WJ (1992) Structural requirements for galanin inhibition of pentagastrin-stimulated gastric acid secretion in conscious rats. Eur J Pharmacol 214:53–57PubMedGoogle Scholar
  115. Mussap CJ, Geraghty DP, Burcher E (1993) Tachykinin receptors: a radioligand binding perspective. J Neurochem 60:1987–2009PubMedGoogle Scholar
  116. Neil GA, Blum A, Weinstock JV (1991) Substance P but not vasoactive intestinal peptide modulates immunoglobulin secretion in murine schistosomiasis. Cell Immunol 135:394–401PubMedGoogle Scholar
  117. Nilsson J, von Euler AM, Dalsgaard CJ (1985) Stimulation of connective tissue cell growth by substance P and substance K. Nature 315:61–63PubMedGoogle Scholar
  118. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedGoogle Scholar
  119. Pavlovic S, Daniltchenko M, Tobin DJ, Hagen E, Hunt SP, Klapp BF, Arck PC, Peters EM (2008) Further exploring the brain-skin connection: stress worsens dermatitis via substance P-dependent neurogenic inflammation in mice. J Invest Dermatol 128:434–446PubMedGoogle Scholar
  120. Peters EM, Ericson ME, Hosoi J, Seiffert K, Hordinsky MK, Ansel JC, Paus R, Scholzen TE (2006) Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 126:1937–1947PubMedGoogle Scholar
  121. Pincelli C, Fantini F, Romualdi P, Sevignani C, Lesa G, Benassi L, Giannetti A (1992) Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol 98:421–427PubMedGoogle Scholar
  122. Pothoulakis C, Castagliuolo I, LaMont JT, Jaffer A, O'Keane JC, Snider RM, Leeman SE (1994) CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci USA 91:947–951PubMedGoogle Scholar
  123. Potter EK, Smith-White MA (2005) Galanin modulates cholinergic neurotransmission in the heart. Neuropeptides 39:345–348PubMedGoogle Scholar
  124. Puneet P, Hegde A, Ng SW, Lau HY, Lu J, Moochhala SM, Bhatia M (2006) Preprotachykinin-A gene products are key mediators of lung injury in polymicrobial sepsis. J Immunol 176:3813–3820PubMedGoogle Scholar
  125. Regoli D, Boudon A, Fauchere JL (1994) Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46:551–599PubMedGoogle Scholar
  126. Richardson JD, Vasko MR (2002) Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 302:839–845PubMedGoogle Scholar
  127. Rossmanith WG, Clifton DK, Steiner RA (1996) Galanin gene expression in hypothalamic GnRH-containing neurons in the rat: a model for autocrine regulation. Horm Metab 28:257–266Google Scholar
  128. Salvatore C, Hershey J, Corcoran H et al (2008) Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324:416–421PubMedGoogle Scholar
  129. Sanger GJ (2004) Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Pharmacol 141:1303–1312PubMedGoogle Scholar
  130. Santic R, Fenninger K, Graf K et al (2006) Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene. J Mol Neurosci 29:145–152PubMedGoogle Scholar
  131. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE (2006) The role of neuropeptides in psoriasis. Br J Dermatol 155:876–882PubMedGoogle Scholar
  132. Sarnelli G, Vanden Berghe P, Raeymaekers P, Janssens J, Tack J (2004) Inhibitory effects of galanin on evoked [Ca2+]i responses in cultured myenteric neurons. Am J Physiol Gastrointest Liver Physiol 286:G1009–G1014PubMedGoogle Scholar
  133. Schepp W, Prinz C, Tatge C, Håkanson R, Schusdziarra V, Classen M (1990) Galanin inhibits gastrin release from isolated rat gastric G-cells. Am J Physiol 258:G596–G602PubMedGoogle Scholar
  134. Schmidhuber SM, Santic R, Tam CW, Bauer JW, Kofler B, Brain SD (2007) Galanin-like peptides exert potent vasoactive functions in vivo. J Invest Dermatol 127:716–721PubMedGoogle Scholar
  135. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC (1998) Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7:81–96PubMedGoogle Scholar
  136. Shen PJ, Larm JA, Gundlach AL (2003) Expression and plasticity of galanin systems in cortical neurons, oligodendrocyte progenitors and proliferative zones in normal brain and after spreading depression. Eur J Neurosci 18:1362–1376PubMedGoogle Scholar
  137. Shepherd AJ, Beresford LJ, Bell EB, Miyan JA (2005) Mobilisation of specific T cells from lymph nodes in contact sensitivity requires substance P. J Neuroimmunol 164:115–123PubMedGoogle Scholar
  138. Sluka KA, Westlund KN (1993) Behavioral and immunohistochemical changes in an experimental arthritis model in rats. Pain 55:367–377PubMedGoogle Scholar
  139. Sluka KA, Milton MA, Willis WD, Westlund KN (1997) Differential roles of neurokinin 1 and neurokinin 2 receptors in the development and maintenance of heat hyperalgesia induced by acute inflammation. Br J Pharmacol 120:1263–1273PubMedGoogle Scholar
  140. Stead RH, Tomioka M, Quinonez G, Simon GT, Felten SY, Bienenstock J (1987) Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Natl Acad Sci USA 84:2975–2979PubMedGoogle Scholar
  141. Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger T (2003) Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 139:1479–1488PubMedGoogle Scholar
  142. Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181PubMedGoogle Scholar
  143. Takatsu Y, Matsumoto H, Ohtaki T, Kumano S, Kitada C, Onda H, Nishimura O, Fujino M (2001) Distribution of galanin-like peptide in the rat brain. Endocrinology 142:1626–1634PubMedGoogle Scholar
  144. Talero E, Sánchez-Fidalgo S, Ramón Calvo J, Motilva V (2006) Galanin in the trinitrobenzene sulfonic acid rat model of experimental colitis. Int Immunopharmacol 6:1404–1412PubMedGoogle Scholar
  145. Talero E, Sánchez-Fidalgo S, Calvo JR, Motilva V (2007) Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regul Pept 141:96–104PubMedGoogle Scholar
  146. Tanaka T, Danno K, Ikai K, Imamura S (1988) Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol 90:399–401PubMedGoogle Scholar
  147. Tatemoto K, Rökaeus A, Jörnvall H, McDonald TJ, Mutt V (1983) Galanin – a novel biologically active peptide from porcine intestine. FEBS Lett 164:124–128PubMedGoogle Scholar
  148. Umer A, Ługowska H, Sein-Anand J, Rekowski P, Ruczyński J, Petrusewicz J, Korolkiewicz RP (2005) The contractile effects of several substituted short analogues of porcine galanin in isolated rat jejunal and colonic smooth muscle strips. Pharmacol Res 52:283–289PubMedGoogle Scholar
  149. Vachon P, Masse R, Gibbs BF (2004) Substance P and neurotensin are up-regulated in the lumbar spinal cord of animals with neuropathic pain. Can J Vet Res 68:86–92PubMedGoogle Scholar
  150. Viac J, Gueniche A, Doutremepuich JD, Reichert U, Claudy A, Schmitt D (1996) Substance P and keratinocyte activation markers: an in vitro approach. Arch Dermatol Res 288:85–90PubMedGoogle Scholar
  151. Von Euler US, Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72:74–87Google Scholar
  152. Walsh DA, McWilliams F (2006) Tachykinins and the cardiovascular system. Curr Drug Targets 7:1031–1042PubMedGoogle Scholar
  153. Weber M, Birklein F, Neundörfer B, Schmelz M (2001) Facilitated neurogenic inflammation in complex regional pain syndrome. Pain 91:251–257PubMedGoogle Scholar
  154. Woodbury RG, Miller HR, Huntley JF, Newlands GF, Palliser AC, Wakelin D (1984) Mucosal mast cells are functionally active during spontaneous expulsion of intestinal nematode infections in rat. Nature 312:450–452PubMedGoogle Scholar
  155. Xu XJ, Hao JX, Wiesenfeld-Hallin Z, Håkanson R, Folkers K, Hökfelt T (1991) Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. Neuroscience 42:731–737PubMedGoogle Scholar
  156. Xu XJ, Hökfelt T, Bartfai T, Wiesenfeld-Hallin Z (2000) Galanin and spinal nociceptive mechanisms: Recent advances and therapeutic implications. Neuropeptides 34:137–147PubMedGoogle Scholar
  157. Yau WM, Dorsett JA, Youther ML (1986) Evidence for galanin as an inhibitory neuropeptide on myenteric cholinergic neurons in the guinea pig small intestine. Neurosci Lett 72:305–308PubMedGoogle Scholar
  158. Zhang H, Hegde A, Ng SW, Adhikari S, Moochhala SM, Bhatia M (2007) Hydrogen sulfide up-regulates substance P in polymicrobial sepsis-associated lung injury. J Immunol 179:4153–4160PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Elizabeth S. Fernandes
    • 1
  • Sabine M. Schmidhuber
    • 1
  • Susan D. Brain
    • 1
    Email author
  1. 1.Cardiovascular DivisionKing’s College LondonLondonUK

Personalised recommendations